Relevant molecular pathways and targeted agents in TNBC (Homo sapiens)

From WikiPathways

Jump to: navigation, search
1alpelisibPTENPDK1mTORC1PI3kdactolisibINPP48buparlisibAKT1everolimusMTORIRS1pictilisibtemsirolimusTCS1/2PIP2 MK2206S6K4EBP1PI3kmTORC2PIP3


Description

Schematic of the most relevant molecular pathways and targeted agents in TNBC. Tyrosine kinase receptor is activated upon binding of growth factors leading to activation of signaling pathways. PI3K/AKT pathway and inhibitor drugs: Phosphorylated PI3K activate AKT. The activation of AKT triggers downstream protein complexes mTORC activation that initiate gene transcription and promote cell growth. AR pathway is activated in LAR subtype tumors. Platinum drugs act through DNA damaging mechanism. PARP inhibitors induce “synthetic lethality” in BRCA deficient tumors.

Try the New WikiPathways

View approved pathways at the new wikipathways.org.

Quality Tags

Ontology Terms

 

Bibliography

  1. Vagia E, Mahalingam D, Cristofanilli M; ''The Landscape of Targeted Therapies in TNBC.''; Cancers (Basel), 2020 PubMed Europe PMC Scholia

History

CompareRevisionActionTimeUserComment
122330view12:36, 18 March 2022AndraNew pathway

External references

DataNodes

View all...
NameTypeDatabase referenceComment
4EBP1GeneProduct
AKT1GeneProduct207 (Entrez Gene)
INPP48GeneProduct
IRS1GeneProduct3667 (Entrez Gene)
MK2206Metabolite
MTORGeneProduct2475 (Entrez Gene)
PDK1GeneProduct5163 (Entrez Gene)
PI3kGeneProduct
PIP2 GeneProduct
PIP3GeneProduct
PTENGeneProduct5728 (Entrez Gene)
S6KGeneProduct
TCS1/2GeneProduct
alpelisibMetaboliteQ27074391 (Wikidata)
buparlisibMetaboliteQ25100534 (Wikidata)
dactolisibMetaboliteQ4835503 (Wikidata)
everolimusMetaboliteQ421052 (Wikidata)
mTORC1GeneProduct
mTORC2GeneProduct
pictilisibMetaboliteQ27088388 (Wikidata)
temsirolimusMetaboliteQ7699074 (Wikidata)

Annotated Interactions

No annotated interactions

Personal tools